(ACHV) Achieve Life Sciences - Overview
Stock: Cytisinicline, Treatment, Smoking, Withdrawal, Symptom
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 84.1% |
| Relative Tail Risk | -13.1% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.73 |
| Alpha | 7.74 |
| Character TTM | |
|---|---|
| Beta | 1.236 |
| Beta Downside | 1.344 |
| Drawdowns 3y | |
|---|---|
| Max DD | 80.11% |
| CAGR/Max DD | -0.09 |
Description: ACHV Achieve Life Sciences January 17, 2026
Achieve Life Sciences, Inc. (NASDAQ: ACHV) is a late-stage biotech focused on nicotine-independence therapies. Its lead product, cytisinicline-a plant-derived alkaloid that modulates nicotinic acetylcholine receptors to blunt withdrawal symptoms-is being pursued for commercialization in Canada, the United States, and the United Kingdom under a license and supply agreement with Sopharma AD and the University of Bristol. The company is headquartered in Bothell, Washington.
Key industry context: the North American nicotine-cessation market is estimated at roughly $2.5 billion in 2024 and is projected to grow 4-5 % annually, driven by stricter tobacco-control policies and increasing consumer demand for non-combustible alternatives. Cytisinicline is currently in Phase 3 trials; assuming successful outcomes, a U.S. NDA filing could occur by late 2025, positioning ACHV against established products such as Pfizer’s Chantix and newer varenicline-free candidates. As of the most recent 10-Q (Q2 2024), the company reported cash and cash equivalents of about $45 million, providing an estimated 12-month runway at current burn rates-a critical KPI for assessing financing risk.
For a deeper quantitative assessment, you may find ValueRay’s analyst platform useful.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -52.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.78 > 0.02 and ΔFCF/TA -26.09 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.78 > 3% & CFO -40.7m > Net Income -52.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 5.14 > 1.5 & < 3 |
| Outstanding Shares: last quarter (34.7m) vs 12m ago 0.96% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.46% > 50% (prev 0.0%; Δ 0.46% > 0%) |
| Interest Coverage Ratio: -67.43 > 6 (EBITDA TTM -51.4m / Interest Expense TTM 765.0k) |
Altman Z'' -15.00
| A: 0.77 (Total Current Assets 50.1m - Total Current Liabilities 9.73m) / Total Assets 52.0m |
| B: -4.72 (Retained Earnings -245.6m / Total Assets 52.0m) |
| C: -1.03 (EBIT TTM -51.6m / Avg Total Assets 50.0m) |
| D: -13.32 (Book Value of Equity -245.4m / Total Liabilities 18.4m) |
| Altman-Z'' Score: -31.22 = D |
What is the price of ACHV shares?
Over the past week, the price has changed by +1.67%, over one month by -14.83%, over three months by -10.34% and over the past year by +32.40%.
Is ACHV a buy, sell or hold?
- StrongBuy: 7
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ACHV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 15.4 | 261.9% |
| Analysts Target Price | 15.4 | 261.9% |
| ValueRay Target Price | 4.3 | 0% |
ACHV Fundamental Data Overview February 03, 2026
Revenue TTM = 228.0k USD
EBIT TTM = -51.6m USD
EBITDA TTM = -51.4m USD
Long Term Debt = 8.67m USD (from longTermDebt, last quarter)
Short Term Debt = 1.26m USD (from shortTermDebt, last quarter)
Debt = 9.96m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -22.0m USD (from netDebt column, last quarter)
Enterprise Value = 184.4m USD (222.5m + Debt 9.96m - CCE 48.1m)
Interest Coverage Ratio = -67.43 (Ebit TTM -51.6m / Interest Expense TTM 765.0k)
EV/FCF = -4.53x (Enterprise Value 184.4m / FCF TTM -40.7m)
FCF Yield = -22.06% (FCF TTM -40.7m / Enterprise Value 184.4m)
FCF Margin = -17.8k% (FCF TTM -40.7m / Revenue TTM 228.0k)
Net Margin = -23.0k% (Net Income TTM -52.3m / Revenue TTM 228.0k)
Gross Margin = 48.68% ((Revenue TTM 228.0k - Cost of Revenue TTM 117.0k) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 3.54 (Enterprise Value 184.4m / Total Assets 52.0m)
Interest Expense / Debt = 1.93% (Interest Expense 192.0k / Debt 9.96m)
Taxrate = 21.0% (US default 21%)
NOPAT = -40.7m (EBIT -51.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.14 (Total Current Assets 50.1m / Total Current Liabilities 9.73m)
Debt / Equity = 0.30 (Debt 9.96m / totalStockholderEquity, last quarter 33.6m)
Debt / EBITDA = 0.43 (negative EBITDA) (Net Debt -22.0m / EBITDA -51.4m)
Debt / FCF = 0.54 (negative FCF - burning cash) (Net Debt -22.0m / FCF TTM -40.7m)
Total Stockholder Equity = 26.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -104.7% (out of range, set to none)
RoE = -196.7% (Net Income TTM -52.3m / Total Stockholder Equity 26.6m)
RoCE = -146.2% (out of range, set to none) (EBIT -51.6m / Capital Employed (Equity 26.6m + L.T.Debt 8.67m))
RoIC = -111.7% (out of range, set to none) (NOPAT -40.7m / Invested Capital 36.5m)
WACC = 10.09% (E(222.5m)/V(232.5m) * Re(10.47%) + D(9.96m)/V(232.5m) * Rd(1.93%) * (1-Tc(0.21)))
Discount Rate = 10.47% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 28.01%
Fair Price DCF = unknown (Cash Flow -40.7m)
EPS Correlation: 79.84 | EPS CAGR: 25.79% | SUE: 4.0 | # QB: 1
Revenue Correlation: 25.21 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.31 | Chg30d=-0.011 | Revisions Net=+0 | Analysts=3
EPS next Year (2026-12-31): EPS=-1.18 | Chg30d=-0.008 | Revisions Net=-1 | Growth EPS=+6.3% | Growth Revenue=+0.0%